SCHEMBL25842164

SCHEMBL25842164

CCCc1c[nH]c2c(CC=C(C)C)cc(C)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.38
MTNR1A P48039 7/20 0.34
MTNR1B P49286 7/20 0.34
HTR1D P28221 2/20 0.33
HTR2A P28223 2/20 0.33
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C19 P33261 2/20 0.31
HPGD P15428 2/20 0.31
HTT P42858 2/20 0.31
ALDH1A1 P00352 1/20 0.31
MEN1 O00255 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30
DRD2 P14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25304444 0.88 HTR2A (0.47) HTR1DHTR2ACYP1A2CYP3A4CYP2D6
SCHEMBL26203869 0.85 GPR84 (0.41) CYP19A1MTNR1AMTNR1BHTR2A
SCHEMBL25842174 0.80 SOS2 (0.46) HTR1DHTR2ACYP1A2CYP2C19ALDH1A1
SCHEMBL25842223 0.77 KDM4E (0.45) CYP1A2CYP3A4CYP2C19HPGDHTT
SCHEMBL25842260 0.76 TNF (0.45) HTR2ACYP3A4CYP2C19HPGDALDH1A1
SCHEMBL26202266 0.73 HTR2A (0.40) HTR1DHTR2ACYP1A2CYP3A4CYP2D6
SCHEMBL25381672 0.73 HTR2A (0.46) HTR1DHTR2ACYP1A2CYP3A4CYP2D6
SCHEMBL29799313 0.73 HTR2A (0.46) HTR1DHTR2ACYP1A2CYP3A4CYP2D6
SCHEMBL25842177 0.72 CYP19A1 (0.35) CYP19A1HTR2ACYP1A2CYP3A4CYP2C19
SCHEMBL25842178 0.69 HTR2A (0.42) CYP19A1MTNR1AMTNR1BHTR1DHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219888-A1 PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING MAGICMED INDUSTRIES INC. (CA) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219888-A1 PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING AANAT, ACAT2, PCYT1A CYP19A1 445/4885MTNR1A 1294/4885MTNR1B 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.